A Study of Brentuximab Vedotin Treatment in Chinese Adults With CD30-Positive Cutaneous T-Cell Lymphoma

A Phase 4, Single Arm, Open Label, Multicenter Study of Brentuximab Vedotin Treatment of Chinese Patients With CD30-Positive Cutaneous T-Cell Lymphoma

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT05442554

Enrollment

Registered

2022-07-05

Start date

2022-11-28

Completion date

2024-08-09

Last updated

2025-09-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

T-Cell Lymphoma

Keywords

Drug Therapy

Brief summary

The main aim is to check the long-term side effects of treatment with Brentuximab Vedotin and to see if that treatment improves symptoms of cluster of differentiation antigen 30 (CD30-Positive) Cutaneous T-Cell Lymphoma in Chinese adults. Participants will receive brentuximab vedotin through the vein on day 1 of each 21 day cycle up to maximum 16 cycles.

Detailed description

The drug being tested in this study is called brentuximab vedotin (SGN-35). Brentuximab vedotin is being tested to treat people who have CD30-positive cutaneous T-Cell lymphoma. The study will enroll approximately 10 patients. Participants will receive a single treatment i.e., brentuximab vedotin monotherapy: • Brentuximab vedotin 1.8 mg/kg Participants will be administered with brentuximab vedotin by intravenous (IV) infusion given for approximately 30 minutes on Day 1 of each 21-day cycle up to 16 cycles followed by the end of treatment (EOT) visit 30 days after receiving the final dose of study drug. Participants with progressive disease (PD) at any time during the study will be discontinued from study drug. This multi-center trial will be conducted in China. Participants will remain in this study for approximately 56 weeks.

Interventions

DRUGBrentuximab vedotin

Brentuximab vedotin IV infusion.

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

1\. Histologically- confirmed cluster of differentiation antigen 30 positive (CD30+) disease by local laboratory assessment and pathology review. 2\. Participants with primary cutaneous anaplastic large cell lymphoma (pcALCL) who have received prior radiation therapy or at least 1 prior systemic therapy, or participants with mycosis fungoides (MF) who have received at least 1 prior systemic therapy for their disease. 3. Eastern Cooperative Oncology Group (ECOG) performance status of ≤2. 4. Suitable venous access for the study-required blood sampling. 5. Participants must have radiographically or clinically measurable or evaluable disease. 6\. Recovered (i.e., Grade 1 toxicity) from the reversible effects of prior antineoplastic therapy. -

Exclusion criteria

1. A concurrent diagnosis of systemic anaplastic large cell lymphoma (ALCL), or other non-Hodgkin lymphoma (excluding lymphomatoid papulosis \[LyP\]). 2. A concurrent diagnosis of sézary syndrome (SS) or high blood tumor burden (B2) disease. 3. Corticosteroid therapy for the treatment of cutaneous T-cell lymphoma (CTCL) within 3 weeks of first dose of study drug. 4. Known hypersensitivity to recombinant proteins, murine proteins, or any excipient contained in the drug formulation. 5. Life-threatening illness unrelated to cancer. 6. Severe central nervous system (CNS), pulmonary, renal, or hepatic disease not related to the participant's cancer. 7. Known active cerebral/meningeal disease, including signs or symptoms of progressive multifocal leukoencephalopathy (PML). 8. Known human immunodeficiency virus (HIV) positive. 9. Known hepatitis B surface antigen positive or known or suspected active hepatitis C infection. 10. Any severe active systemic viral, bacterial, or fungal infection within 1 week before first study drug dose requiring systemic antimicrobial therapy. (Oral antibiotics for prophylaxis are allowed.) 11. Receiving antibody-directed or immunoglobulin-based immune therapy (eg, immunoglobulin replacement, other monoclonal antibody therapies) within 12 weeks of first study drug dose. 12. Any of the following cardiovascular conditions or values within 6 months before the first dose of study drug: * Myocardial infarction within 6 months of enrollment. * New York Heart Association (NYHA) Class III or IV heart failure. * Evidence of current uncontrolled cardiovascular conditions, including cardiac arrhythmias, congestive heart failure (CHF), angina, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities. 13. History of another primary malignancy not in remission for at least 3 years. The following are exempt from the 3-year limit: completely resected in situ carcinoma, such as nonmelanoma skin cancer and cervical carcinoma in situ on biopsy or a squamous intraepithelial lesion on Pap smear. 14. Oral retinoid therapy for any indication within 3 weeks of the first dose of study drug. 15. History of pancreatitis or significant risk factors for developing pancreatitis (eg, prior pancreatitis, uncontrolled hyperlipidemia, excessive alcohol consumption, uncontrolled diabetes mellitus, biliary tract disease, and medications known to increase triglyceride levels or to be associated with pancreatic toxicity).

Design outcomes

Primary

Measure	Time frame	Description
Overall Response Rate (ORR) Lasting at Least 4 Months in Participants With CD30+ MF or pcALCL	Up to 58 weeks	ORR is defined as the percentage of participants who achieve complete response (CR) or partial response (PR) that lasts at least 4 months. CR is defined as complete disappearance of all clinical evidence of disease and PR is defined as regression of measurable disease. ORR was determined based on Global Response Score (GRS) which consisted of a skin assessment by the investigator using the modified severity-weighted assessment tool (mSWAT), nodal and visceral involvement using computed tomography (CT) scan, and for the participants with mycosis fungoides (MF) only, detection of circulating Sezary cells. Response Criteria were based on International Society for Cutaneous Lymphomas (ISCL), United States Cutaneous Lymphoma Consortium (USCLC) and European Organisation for Research and Treatment of Cancer (EORTC) Consensus guidelines.

Secondary

Measure	Time frame	Description
Overall Response Rate (ORR)	Up to 58 weeks	ORR is defined as the percentage of participants who achieve complete response (CR) or partial response (PR). CR is defined as complete disappearance of all clinical evidence of disease and PR is defined as regression of measurable disease. ORR was determined based on GRS which consisted of a skin assessment by the investigator using the mSWAT, nodal and visceral involvement using CT scan, and for the participants with MF only, detection of circulating Sezary cells. Response Criteria were based on ISCL, USCLC and EORTC Consensus guidelines.
Duration of Response (DOR)	Up to 58 weeks	Duration of response was assessed in participants with CR or PR and is defined as the time between first documentation of response and progressive disease (PD). Response criteria were based on ISCL, USCLC and EORTC Consensus guidelines. Participants who were lost to follow-up, withdrew consent, or discontinued treatment due to undocumented PD after the last adequate disease assessment were censored at the last disease assessment.
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)	From first dose of study drug through 30 days after the last dose of study drug (up to approximately 58 weeks)	An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (e.g. a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. TEAE is defined as an adverse event with an onset that occurs after receiving study drug. SAE is any AE that results in death, is life-threatening, requires inpatient hospitalization or prolongation of an existing hospitalization, results in significant disability or incapacity, is a congenital anomaly/birth defect or is a medically important event. TEAE and SAE were determined as per National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0.
Changes From Baseline in Participant's Vital Sign: Systolic and Diastolic Blood Pressure	Baseline, at end of treatment (approximately Week 54)	Vital signs included seated blood pressure (systolic and diastolic) measurements.
Changes From Baseline in Participant's Vital Sign: Heart Rate	Baseline, at end of treatment (approximately Week 54)	Vital signs included heart rate (beats per minute) measurements.
Changes From Baseline in Participant's Vital Sign: Body Temperature	Baseline, at end of treatment (approximately Week 54)	Vital signs included body temperature (degree Celsius) measurements.
Number of Participants From Baseline to Worst Post-Baseline Assessment Categories Based on Eastern Cooperative Oncology Group (ECOG) Performance Status Scale	Baseline up to 30 days after the last dose of study drug (up to approximately 58 weeks)	ECOG scale was used to assess performance status of participants. Grades range from 0 (fully active) to 5 (dead) where Grade 0: Normal activity. Grade 1: Symptoms but ambulatory. Grade 2: In bed \<50% of the time. Grade 3: In bed \>50% of the time. Grade 4: 100% bedridden. Grade 5: Dead. Lower grades indicate improvement. Reported here is the number of participants in each reported baseline grade to their worst post-baseline grade assessment on the ECOG scale.
Change From Baseline in Hematology Parameter: Hemoglobin	Baseline, at end of treatment (approximately Week 54)	—
Change From Baseline in Hematology Parameter: Neutrophil Count	Baseline, at end of treatment (approximately Week 54)	—
Complete Response (CR) Rate	Up to 58 weeks	CR rate is defined as the percentage of participants with CR. CR is defined as complete disappearance of all clinical evidence of disease. CR was determined based on GRS which consisted of a skin assessment by the investigator using the mSWAT, nodal and visceral involvement using computed tomography (CT) scan, and for the participants with MF only, detection of circulating Sezary cells. Response Criteria were based on ISCL, USCLC and EORTC Consensus guidelines.
Change From Baseline in Hematology Parameter: Lymphocyte Count	Baseline, at end of treatment (approximately Week 54)	—
Change From Baseline in Hematology Parameter: Leukocyte Count	Baseline, at end of treatment (approximately Week 54)	—
Change From Baseline in Serum Chemistry Parameter: Alkaline Phosphatase (ALP)	Baseline, at end of treatment (approximately Week 54)	—
Change From Baseline in Serum Chemistry Parameter: Alanine Aminotransferase (ALT)	Baseline, at end of treatment (approximately Week 54)	—
Change From Baseline in Serum Chemistry Parameter: Aspartate Aminotransferase (AST)	Baseline, at end of treatment (approximately Week 54)	—
Change From Baseline in Serum Chemistry Parameter: Total Bilirubin	Baseline, at end of treatment (approximately Week 54)	—
Change From Baseline in Serum Chemistry Parameter: Lipase	Baseline, at end of treatment (approximately Week 54)	—
Change From Baseline in Serum Chemistry Parameter: Amylase	Baseline, at end of treatment (approximately Week 54)	—
Change From Baseline in Hematology Parameter: Platelet Count	Baseline, at end of treatment (approximately Week 54)	—

Countries

China

Participant flow

Recruitment details

Participants took part in the study at 3 investigative sites in China from 28 November 2022 to 09 August 2024.

Pre-assignment details

Participants with cluster of differentiation 30-positive mycosis fungoides (CD30+ MF) or primary cutaneous anaplastic large cell lymphoma (pcALCL) histologically confirmed by local pathology assessment participated in the study to receive brentuximab vedotin.

Participants by arm

Arm	Count
Brentuximab Vedotin Participants received brentuximab vedotin 1.8 mg/kg, IV on Day 1 of each 21-day cycle for up to a total of 16 cycles.	10
Total	10

Withdrawals & dropouts

Period	Reason	FG000
Overall Study	Adverse Event	1

Baseline characteristics

Characteristic	Brentuximab Vedotin
Age, Continuous	57.1 years STANDARD_DEVIATION 13.26
Ethnicity (NIH/OMB) Hispanic or Latino	0 Participants
Ethnicity (NIH/OMB) Not Hispanic or Latino	10 Participants
Ethnicity (NIH/OMB) Unknown or Not Reported	0 Participants
Race (NIH/OMB) American Indian or Alaska Native	0 Participants
Race (NIH/OMB) Asian	10 Participants
Race (NIH/OMB) Black or African American	0 Participants
Race (NIH/OMB) More than one race	0 Participants
Race (NIH/OMB) Native Hawaiian or Other Pacific Islander	0 Participants
Race (NIH/OMB) Unknown or Not Reported	0 Participants
Race (NIH/OMB) White	0 Participants
Sex: Female, Male Female	5 Participants
Sex: Female, Male Male	5 Participants

Adverse events

Event type	EG000 affected / at risk
deaths Total, all-cause mortality	0 / 10
other Total, other adverse events	10 / 10
serious Total, serious adverse events	4 / 10

Outcome results

Primary

Overall Response Rate (ORR) Lasting at Least 4 Months in Participants With CD30+ MF or pcALCL

ORR is defined as the percentage of participants who achieve complete response (CR) or partial response (PR) that lasts at least 4 months. CR is defined as complete disappearance of all clinical evidence of disease and PR is defined as regression of measurable disease. ORR was determined based on Global Response Score (GRS) which consisted of a skin assessment by the investigator using the modified severity-weighted assessment tool (mSWAT), nodal and visceral involvement using computed tomography (CT) scan, and for the participants with mycosis fungoides (MF) only, detection of circulating Sezary cells. Response Criteria were based on International Society for Cutaneous Lymphomas (ISCL), United States Cutaneous Lymphoma Consortium (USCLC) and European Organisation for Research and Treatment of Cancer (EORTC) Consensus guidelines.

Time frame: Up to 58 weeks

Population: The response-evaluable population included a subset of the full analysis set (FAS) participants with measurable disease at baseline and with at least 1 post-baseline response assessment. FAS consisted of all enrolled participants identified as CD30+ and received at least 1 dose of the study drug.

Arm	Measure	Value (NUMBER)
Brentuximab Vedotin	Overall Response Rate (ORR) Lasting at Least 4 Months in Participants With CD30+ MF or pcALCL	60.0 percentage of participants

Secondary